In this trial, patients with NSCLC with PD-L1 immunohistochemical expression ≥1% (28-8 antibody) were recruited and randomised to receive nivolumab or investigator-choice platinum-based chemotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.